Bellicum Announces Clinical Presentations at the 22nd Congress of the European Hematology Association
May 18 2017 - 7:00AM
Overall-cohort abstract on BPX-501 selected for
presentation at Presidential Symposium
Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in
developing novel, controllable cellular immunotherapies for cancers
and orphan inherited blood disorders, today announced that three
abstracts have been accepted for presentation at the 22nd Congress
of the European Hematology Association (EHA) being held in Madrid,
Spain on June 22-25, 2017.
Bellicum’s presentation of the overall cohort of children with
malignant and non-malignant diseases treated with BPX-501 was
selected as one of the Congress’ five best abstracts, and will be
reviewed during the Presidential Symposium.
Additional oral and poster presentations selected include
clinical data on BPX-501 for the treatment of pediatric leukemias,
hemoglobinopathies and erythroid disorders. The abstracts are now
available online at the EHA conference website.
EHA Presentation Details
Oral Presentation - Presidential Symposium
Title: BPX-501 Donor T-Cell Infusion (with
Inducible Caspase 9 Suicide Gene) Facilitates HLA Haploidentical
Stem Cell Transplant in Children with Both Hematological
Malignancies and Non-Malignant ConditionsSession
Title: Presidential SymposiumDate:
Friday, June 23Time: 3:45 – 4:00 PM
CESTLocation: Hall AAbstract
Code: S146
Oral PresentationTitle: Impact
of Post-Transplant Infusion of Donor T-Cells Genetically Modified
with Inducible Caspase 9 Suicide Gene (BPX-501 Cells) on Children
with Leukemia Given Alpha-Beta T-Cell Depleted
Haplo-HSCTSession Title: Stem cell transplantation
– Clinical 1Date: Saturday, June
24Time: 5:00 – 5:15 PM
CESTLocation: Room N103Abstract
Code: S495
Poster PresentationTitle: The
Use of BPX-501 Donor T-Cell Infusion (with Inducible Caspase 9
Suicide Gene) Together with HLA-Haploidentical Stem Cell Transplant
to Treat Children with Hemoglobinopathies and Erythroid
DisordersSession Title: Stem cell transplantation
– Clinical 1Date: Friday, June
23Time: 5:15 – 6:45 PM
CESTLocation: Poster Area (Hall 7)Abstract
Code: P381
About Bellicum PharmaceuticalsBellicum is a
clinical stage biopharmaceutical company focused on discovering and
developing cellular immunotherapies for cancers and orphan
inherited blood disorders. Bellicum is using its proprietary
Chemical Induction of Dimerization (CID) technology platform to
engineer and control components of the immune system. Bellicum is
developing next-generation product candidates in some of the most
important areas of cellular immunotherapy, including hematopoietic
stem cell transplantation (HSCT), and CAR T and TCR cell therapies.
More information can be found at www.bellicum.com.
Forward-Looking StatementThis press release
contains forward-looking statements for purposes of the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
Bellicum may, in some cases, use terms such as "predicts,"
"believes," "potential," "proposed," "continue," “designed,”
"estimates," "anticipates," "expects," "plans," "intends," "may,"
"could," "might," "will," "should" or other words that convey
uncertainty of future events or outcomes to identify these
forward-looking statements. Forward-looking statements include
statements regarding our intentions, beliefs, projections, outlook,
analyses or current expectations concerning, among other things:
our research and development activities relating to our BPX-501,
CID, CAR T and TCR programs; the effectiveness of BPX-501; its
possible range of application and potential curative effects and
safety in the treatment of diseases; and, the timing and success of
our clinical trials. Various factors may cause differences between
Bellicum’s expectations and actual results as discussed in greater
detail under the heading “Risk Factors” in Bellicum’s filings with
the Securities and Exchange Commission, including without
limitation our annual report on Form 10-K for the year ended
December 31, 2016 and our report on Form 10-Q for the quarter ended
March 31, 2017. Any forward-looking statements that Bellicum makes
in this press release speak only as of the date of this press
release. Bellicum assumes no obligation to update our
forward-looking statements whether as a result of new information,
future events or otherwise, after the date of this press
release.
Investors:
Bellicum Pharmaceuticals, Inc.
Alan Musso, CFO
832-384-1116
amusso@bellicum.com
Media:
BMC Communications
Brad Miles
646-513-3125
bmiles@bmccommunications.com
Bellicum Pharmaceuticals (NASDAQ:BLCM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bellicum Pharmaceuticals (NASDAQ:BLCM)
Historical Stock Chart
From Apr 2023 to Apr 2024